Concepts (139)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cytochrome P-450 CYP1A1 | 7 | 2017 | 52 | 1.690 |
Why?
|
| Enzyme Inhibitors | 9 | 2014 | 458 | 1.340 |
Why?
|
| Quinones | 3 | 2016 | 17 | 1.260 |
Why?
|
| Cytochrome P-450 CYP1A2 | 5 | 2017 | 28 | 1.180 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2016 | 159 | 1.060 |
Why?
|
| Flavones | 4 | 2023 | 12 | 0.770 |
Why?
|
| Cytochrome P-450 Enzyme System | 5 | 2023 | 98 | 0.690 |
Why?
|
| Antineoplastic Agents | 4 | 2016 | 1019 | 0.610 |
Why?
|
| Naphthoquinones | 1 | 2017 | 41 | 0.520 |
Why?
|
| Anthraquinones | 1 | 2017 | 9 | 0.510 |
Why?
|
| Proto-Oncogene Proteins c-pim-1 | 1 | 2016 | 5 | 0.490 |
Why?
|
| Dioxanes | 1 | 2015 | 11 | 0.480 |
Why?
|
| Quantitative Structure-Activity Relationship | 3 | 2019 | 110 | 0.460 |
Why?
|
| Models, Molecular | 10 | 2019 | 876 | 0.450 |
Why?
|
| Hydrocortisone | 1 | 2015 | 93 | 0.440 |
Why?
|
| Structure-Activity Relationship | 10 | 2016 | 506 | 0.410 |
Why?
|
| Breast Neoplasms | 3 | 2014 | 1723 | 0.380 |
Why?
|
| Molecular Structure | 4 | 2025 | 570 | 0.360 |
Why?
|
| Alkynes | 1 | 2012 | 52 | 0.360 |
Why?
|
| Ethers | 1 | 2012 | 21 | 0.360 |
Why?
|
| Ligands | 6 | 2017 | 388 | 0.340 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2013 | 307 | 0.340 |
Why?
|
| Isoflavones | 2 | 2025 | 132 | 0.290 |
Why?
|
| Humans | 23 | 2025 | 43102 | 0.270 |
Why?
|
| Drug Design | 3 | 2017 | 186 | 0.260 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2014 | 62 | 0.250 |
Why?
|
| Neovascularization, Physiologic | 2 | 2014 | 80 | 0.250 |
Why?
|
| Prostatic Neoplasms | 1 | 2016 | 1092 | 0.250 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2006 | 26 | 0.240 |
Why?
|
| Protein Binding | 3 | 2017 | 1082 | 0.230 |
Why?
|
| Pueraria | 1 | 2025 | 4 | 0.230 |
Why?
|
| Coumarins | 2 | 2019 | 45 | 0.230 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2005 | 127 | 0.230 |
Why?
|
| Sesquiterpenes | 1 | 2025 | 38 | 0.230 |
Why?
|
| Receptors, Estrogen | 1 | 2025 | 183 | 0.210 |
Why?
|
| Enzyme Activators | 1 | 2003 | 11 | 0.200 |
Why?
|
| Protein Kinase C | 1 | 2003 | 124 | 0.190 |
Why?
|
| Substrate Specificity | 3 | 2017 | 219 | 0.190 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2016 | 1124 | 0.180 |
Why?
|
| Catalytic Domain | 4 | 2014 | 118 | 0.160 |
Why?
|
| Nicotine | 1 | 2023 | 302 | 0.160 |
Why?
|
| Metabolic Detoxication, Phase I | 1 | 2019 | 3 | 0.150 |
Why?
|
| Xenobiotics | 1 | 2019 | 16 | 0.150 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2016 | 157 | 0.140 |
Why?
|
| Binding Sites | 4 | 2014 | 671 | 0.130 |
Why?
|
| Liver | 2 | 2017 | 511 | 0.130 |
Why?
|
| Estradiol | 2 | 2017 | 268 | 0.130 |
Why?
|
| Pterocarpans | 1 | 2017 | 25 | 0.130 |
Why?
|
| Enzyme Assays | 1 | 2017 | 13 | 0.130 |
Why?
|
| Phenylalanine | 1 | 2017 | 25 | 0.130 |
Why?
|
| Osteogenesis | 1 | 2017 | 57 | 0.130 |
Why?
|
| Bone Marrow Cells | 1 | 2017 | 79 | 0.130 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2017 | 99 | 0.130 |
Why?
|
| Osteoporosis | 1 | 2017 | 45 | 0.130 |
Why?
|
| Mesenchymal Stem Cells | 1 | 2017 | 72 | 0.120 |
Why?
|
| Steroid 21-Hydroxylase | 1 | 2015 | 2 | 0.120 |
Why?
|
| Steroid 11-beta-Hydroxylase | 1 | 2015 | 3 | 0.120 |
Why?
|
| Steroid 17-alpha-Hydroxylase | 1 | 2015 | 10 | 0.120 |
Why?
|
| Patents as Topic | 1 | 2015 | 14 | 0.120 |
Why?
|
| NADP | 2 | 2014 | 37 | 0.120 |
Why?
|
| Stem Cells | 1 | 2017 | 152 | 0.120 |
Why?
|
| Adipose Tissue | 1 | 2017 | 182 | 0.120 |
Why?
|
| Lipid Metabolism | 1 | 2017 | 148 | 0.120 |
Why?
|
| Cell Proliferation | 2 | 2025 | 1455 | 0.110 |
Why?
|
| Cell Line, Tumor | 4 | 2016 | 2676 | 0.110 |
Why?
|
| Hydrogen Bonding | 2 | 2012 | 144 | 0.100 |
Why?
|
| Thiazoles | 1 | 2014 | 76 | 0.100 |
Why?
|
| Protein Structure, Tertiary | 2 | 2005 | 423 | 0.100 |
Why?
|
| High-Throughput Screening Assays | 1 | 2013 | 74 | 0.100 |
Why?
|
| Rats | 2 | 2012 | 3735 | 0.100 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2013 | 51 | 0.100 |
Why?
|
| Time Factors | 1 | 2017 | 1857 | 0.090 |
Why?
|
| Kinetics | 3 | 2014 | 695 | 0.090 |
Why?
|
| Animals | 6 | 2014 | 16992 | 0.090 |
Why?
|
| Thermodynamics | 1 | 2012 | 229 | 0.090 |
Why?
|
| Oxidative Stress | 1 | 2017 | 1003 | 0.090 |
Why?
|
| Estrogen Antagonists | 1 | 2010 | 30 | 0.080 |
Why?
|
| Computer Simulation | 1 | 2012 | 408 | 0.080 |
Why?
|
| Estrogens | 1 | 2010 | 203 | 0.070 |
Why?
|
| Estrogen Receptor alpha | 2 | 2025 | 121 | 0.070 |
Why?
|
| Cells, Cultured | 2 | 2017 | 1621 | 0.070 |
Why?
|
| Female | 4 | 2017 | 24698 | 0.060 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2006 | 29 | 0.060 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2005 | 11 | 0.060 |
Why?
|
| Umbilical Cord | 1 | 2005 | 14 | 0.060 |
Why?
|
| alpha-Synuclein | 1 | 2006 | 61 | 0.060 |
Why?
|
| tau Proteins | 1 | 2006 | 186 | 0.050 |
Why?
|
| Nitriles | 1 | 2004 | 81 | 0.050 |
Why?
|
| Fluorometry | 2 | 2014 | 17 | 0.050 |
Why?
|
| Quinolines | 1 | 2004 | 78 | 0.050 |
Why?
|
| Lactams | 1 | 2003 | 10 | 0.050 |
Why?
|
| Pyrrolidinones | 1 | 2003 | 11 | 0.050 |
Why?
|
| Radioligand Assay | 1 | 2003 | 65 | 0.050 |
Why?
|
| Parkinson Disease | 1 | 2006 | 210 | 0.050 |
Why?
|
| Binding, Competitive | 1 | 2003 | 109 | 0.050 |
Why?
|
| Dimerization | 1 | 2003 | 112 | 0.050 |
Why?
|
| Carcinogens | 1 | 2023 | 126 | 0.050 |
Why?
|
| Isoenzymes | 1 | 2003 | 168 | 0.050 |
Why?
|
| Endothelial Cells | 1 | 2005 | 329 | 0.050 |
Why?
|
| Calcium | 1 | 2003 | 491 | 0.040 |
Why?
|
| Phytoestrogens | 1 | 2017 | 39 | 0.030 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2017 | 66 | 0.030 |
Why?
|
| Vascular Diseases | 1 | 2017 | 33 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2006 | 2157 | 0.030 |
Why?
|
| Metabolic Diseases | 1 | 2017 | 40 | 0.030 |
Why?
|
| Male | 1 | 2016 | 23409 | 0.030 |
Why?
|
| Nervous System Diseases | 1 | 2017 | 77 | 0.030 |
Why?
|
| Enzyme Activation | 1 | 2017 | 462 | 0.030 |
Why?
|
| Chorioallantoic Membrane | 1 | 2014 | 11 | 0.030 |
Why?
|
| Chick Embryo | 1 | 2014 | 79 | 0.030 |
Why?
|
| Cell Line, Transformed | 1 | 2014 | 95 | 0.030 |
Why?
|
| Laminin | 1 | 2014 | 58 | 0.030 |
Why?
|
| Proteoglycans | 1 | 2014 | 49 | 0.030 |
Why?
|
| Microfilament Proteins | 1 | 2014 | 72 | 0.030 |
Why?
|
| Drug Combinations | 1 | 2014 | 104 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2017 | 638 | 0.030 |
Why?
|
| Collagen | 1 | 2014 | 181 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2014 | 290 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2014 | 237 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2013 | 125 | 0.020 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2014 | 188 | 0.020 |
Why?
|
| Small Molecule Libraries | 1 | 2013 | 62 | 0.020 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2013 | 184 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 2014 | 321 | 0.020 |
Why?
|
| Crystallography, X-Ray | 1 | 2012 | 280 | 0.020 |
Why?
|
| Response Elements | 1 | 2010 | 55 | 0.020 |
Why?
|
| Cell Movement | 1 | 2014 | 655 | 0.020 |
Why?
|
| Receptors, Progesterone | 1 | 2010 | 92 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2010 | 408 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2010 | 347 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2010 | 592 | 0.020 |
Why?
|
| Spectrometry, Mass, Fast Atom Bombardment | 1 | 2006 | 10 | 0.020 |
Why?
|
| United States | 1 | 2017 | 5205 | 0.010 |
Why?
|
| Neoplasms | 1 | 2017 | 1377 | 0.010 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2006 | 301 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2006 | 986 | 0.010 |
Why?
|
| Middle Aged | 1 | 2017 | 12222 | 0.010 |
Why?
|
| Adult | 1 | 2017 | 13872 | 0.010 |
Why?
|
| Mice | 1 | 2010 | 6644 | 0.010 |
Why?
|